Navigation Links
Arno Therapeutics Announces New Ticker Symbol
Date:7/17/2008

FAIRFIELD, N.J., July 17 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), today announced that its stock ticker symbol on the OTC Bulletin Board has changed from "LRRI.OB" to "ARNI.OB" effective July 17, 2008.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR- 12 is a potential first-in-class, orally available PI3-k/Akt inhibitor undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including those described under the caption "Risk Factors" in our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2008. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Silence Therapeutics Announces Successful Opposition of Glover Patent
3. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
4. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
5. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
6. Nabriva Therapeutics Announces Appointment of New CEO
7. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
8. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
9. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
10. Tobira Therapeutics Inc. Announces Senior Management Team
11. Duska Therapeutics Obtains Standard & Poors Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017  PrimeVax ... , will be presenting at the Annual Biocom Global ... on March 2, at 11:15 AM, at the Torrey ... are thankful to the organizers at Biocom who have ... this international symposium of biotechnology companies, investors, and clinical ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider ... the world, is pleased to announce the launch of a new scholarship for young ... fields. , This merit-based scholarship is open to all high school seniors, 17 years ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside ... , Perkins joins Pennside after more than a decade with leading market ...
(Date:2/21/2017)... ... 21, 2017 , ... During HIMSS 2017, CloudMine, a secure, ... a partnership with Redox, a leader in cloud-based healthcare integration and API services. ... keeping data secure in the cloud. , The digital health developers, and various ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
Breaking Biology News(10 mins):